AACR 2021: A novel humanized B-hPD-1/hPD-L1/hTIGIT mouse model reveals enhanced efficacy of combined TIGIT and PD-L1 blockade against cancer
- Competitive binding of TIGIT to CD155 and CD112 prevents signaling through CD226, which is an NK activating receptor that contributes to anti-tumor responses.
- Biocytogen established a novel humanized B-hPD-1/hPD-L1/hTIGIT mouse model to preclinically evaluate in vivo efficacy of combined human TIGIT and PD-1/PD-L1 blocking agents.
- Anti-human PD-L1 and anti-human TIGIT antibodies synergize to inhibit tumor growth of MC38-hPD-L1 cells in B-hPD-1/hPD-L1/hTIGIT mice.
- B-hPD-1/hPD-L1/hTIGIT mice are a useful tool for investigating the in vivo efficacy of TIGIT therapeutic candidates alone, or in combination with PD-1/PD-L1 antibodies.